Stem cell therapy for autism only in approved clinical trials: Centre

Why in the News

The Union Health Ministry has directed States and Union Territories to ensure that stem cell therapy is offered as standard clinical care only for disease conditions and indications the Ministry has approved, with its use for Autism Spectrum Disorder (ASD) restricted to duly approved clinical trials. The advisory, issued on September 16, follows the Supreme Court’s judgment of January 30, 2026 in Yash Charitable Trust & Ors. v. Union of India & Ors., and reiterates the existing regulatory framework rather than creating a new one. The problem it addresses is a gap between practice and evidence. Stem cell interventions have continued to be offered for autism as commercial clinical services even though an Indian Council of Medical Research (ICMR) review found the available evidence does not support them.

What does the advisory direct?

1. Approved indications only: Stem cell therapy may be offered as standard clinical care only for disease conditions and indications approved by the Ministry.
2. Autism confined to trials: For ASD, therapeutic use of any type of stem cell must remain confined to duly approved clinical trials.
3. The governing guidelines: Such trials must accord with the National Guidelines for Stem Cell Research, 2017, issued by the ICMR and the Department of Biotechnology.
4. The commercial bar: Interventions not approved for routine clinical use, including those offered for autism, must not be provided as routine, standard or commercial clinical services.

What prompted the advisory?

1. The judgment behind it: The advisory follows the Supreme Court’s January 30, 2026 judgment in Yash Charitable Trust & Ors. v. Union of India & Ors.
2. Who it was issued to: It was issued to States and Union Territories that have adopted the Clinical Establishments (Registration and Regulation) Act, 2010, which is the statute through which clinical establishments are registered and regulated.
3. The dissemination duty: States and Union Territories have been asked to pass the Court’s directions down to State and district regulatory authorities, and to government and private clinical establishments involved in stem cell research, treatment, promotion or administration.

Why does the evidence not support stem cell therapy for autism?

1. The ICMR finding: An ICMR review concluded that the available evidence does not support stem cell therapy over behavioural and supportive therapies for ASD.
2. The review’s own recommendation: It recommended that such therapy be restricted to approved clinical trials rather than offered as care.
3. The practice that continues: Stem cell interventions for autism have continued despite the absence of established evidence supporting them as a standard treatment, which is the conduct the advisory is directed at.

Challenges to regulating unproven stem cell therapy

1. Adoption of the governing Act is voluntary: The Clinical Establishments Act applies only in States that have adopted it, so an advisory routed through it does not reach every clinical establishment in the country. Eg. Several large States have their own clinical establishment legislation and have not adopted the central Act.
   The Fix: Route the same directions through each State’s own clinical establishment law, so coverage does not depend on adoption of the central statute.
2. Guidelines carry no penalty of their own: The National Guidelines for Stem Cell Research, 2017 are guidance rather than statute, so breach is punished only through registration action against the establishment. Eg. Clinics offering unapproved stem cell interventions have continued operating while guidance was in force.
   The Fix: Attach defined penalties for offering unapproved cell based interventions to the rules under the clinical establishment framework.
3. Advertising reaches patients before regulators do: Families encounter claims for stem cell treatment through direct marketing rather than through referral, so demand is created outside the clinical system. Eg. The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 lists conditions for which advertising cures is barred, and enforcement against online claims is thin.
   The Fix: Bring digital advertising of cell based therapies under a prior approval requirement tied to the approved indications list.
4. Desperation drives cross border and unregulated demand: Where no curative treatment exists, families pursue interventions regardless of the evidence, including outside the country. Eg. Stem cell tourism to jurisdictions with weaker oversight is a documented pattern for neurological conditions.
   The Fix: Publish and maintain a public registry of approved indications and approved trial sites, so families can check a claim before paying for it.

Conclusion

The advisory settles the legal position rather than changing it: stem cell therapy for autism is a research question, not a clinical service, and the distinction is now to be enforced through the registration authorities in each State. The instrument’s reach depends on how many States have adopted the Clinical Establishments Act and on whether district regulators act on the directions passed to them. The next measurable step is registration action against establishments that continue to offer the intervention commercially.

Back2Basics: Clinical Establishments (Registration and Regulation) Act, 2010

1. Purpose: It provides for the registration and regulation of clinical establishments, with a view to prescribing minimum standards of facilities and services.
2. Coverage: It applies to all recognised systems of medicine and to both government and private establishments, excluding those run by the armed forces.
3. How it extends to States: It applies directly in Union Territories and in States that adopt it by resolution, since public health is a State subject.
4. Institutional structure: It establishes a National Council for Clinical Establishments and requires State Councils and District Registering Authorities to maintain a national register.

Matching Previous Year Question

“[2017, GS3, 10] Stem cell therapy is gaining popularity in India to treat a wide variety of medical conditions including Leukaemia, Thalassemia, damaged cornea and several burns. Describe briefly what stem cell therapy is and what advantages it has over other treatments?”